Sanofi plans share buybacks, signals more deals post Opella sale
Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a large stake in its consumer health unit.
Sanofi Expects Strong Earnings Growth This Year, Plans $5.2 Billion Buyback
The pharmaceutical company forecasts business earnings per share growth at a low double-digit percentage and plans to launch a $5.2 billion share buyback.
Sanofi Misses on Q4 Earnings & Sales, Expects Higher Profits in 2025
SNY misses Q4 earnings and sales estimates. It expects earnings growth to rebound in 2025. It plans to buy back shares worth 5 billion euro in 2025.
Sanofi Expected to Report Lower Sales, Profit; Size of Buyback in Focus -- Earnings Preview
BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara Research consensus. Sanofi reported a business operating profit of 2.58 billion euros in the year-earlier period.
Sanofi: Q4 Earnings Snapshot
Sanofi (SNY) on Thursday reported fourth-quarter earnings of $728.6 million. The company said it had net income of 29 cents per share. Earnings, adjusted for non-recurring costs and to account for discontinued operations,
Sanofi Plans €5 Billion Buyback, Sees Higher Profit Growth
Sanofi said it will repurchase €5 billion ($5.2 billion) of stock and grow profits faster this year as the drugmaker pivots away from consumer health to focus on fast-growing drugs like its RSV shot.
FiercePharma1h
Sanofi's RSV antibody Beyfortus, after smashing blockbuster sales threshold, still has room to grow in US: execs
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden child could be emerging in the form of Beyfortus. | During its first full year ...
FierceBiotech4h
Sanofi cuts programs tied to multibillion-dollar deals from pipeline
Sanofi has removed a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers of Ablynx, ...
Sanofi reports Q4 IRFS EPS EUR 0.54
Reports Business EPS of EUR 1.31, down 11.0% at CER and down 14.9% reported. Reports Q4 IRFS net sales EUR 10.56B, up 9.1% reported and up ...
STAT8d
Sanofi is warned by the FDA over ‘significant’ problems at a key manufacturing plant
The FDA has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility ...
FiercePharma9d
Sanofi API plant hit with FDA warning letter detailing quality, consistency flubs
Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a ...
Sanofi board proposed dividend of EUR 3.92 for FY24
The Board of Directors met on January 29, 2025; proposes a dividend of EUR 3.92 for 2024, 30th year of consecutive increasesInvest with ...
PMLiVE5h
Sanofi’s Sarclisa combination approved by MHRA for newly diagnosed multiple myeloma
Sanofi’s Sarclisa (isatuximab) has been approved by the Medicines and Healthcare product Regulatory Agency (MHRA) as part of a combination treatment for newly diagnosed multiple myeloma (MM).